A T Hirsch

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. ncbi Gaps in public knowledge of peripheral arterial disease: the first national PAD public awareness survey
    Alan T Hirsch
    Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Ste 300, 1300 S 2nd St, Minneapolis, MN 55454, USA
    Circulation 116:2086-94. 2007
  2. ncbi Special communication: mandate for creation of a national peripheral arterial disease public awareness program: an opportunity to improve cardiovascular health
    Alan T Hirsch
    Division of Epidemiology, University of Minnesota School of Public Health, and Vascular Medicine Program, Minneapolis Heart Institute, Rochester, MN, USA
    Angiology 55:233-42. 2004
  3. ncbi The potential role of angiotensin-converting enzyme inhibition in peripheral arterial disease
    Alan T Hirsch
    Vascular Medicine Program, Minneapolis Heart Institute, and Division of Epidemiology, University of Minnesota School of Public Health, Minneapolis, MN 55454, USA
    Vasc Med 8:273-8. 2003
  4. ncbi Mandate for creation of a national peripheral arterial disease public awareness program: an opportunity to improve cardiovascular health
    Alan T Hirsch
    Division of Epidemiology, University of Minnesota School of Public Health, and Vascular Medicine Program, Minneapolis Heart Institute, Rochester, MN, USA
    Vasc Endovascular Surg 38:121-30. 2004
  5. ncbi Mandate for creation of a national peripheral arterial disease public awareness program: an opportunity to improve cardiovascular health
    Alan T Hirsch
    Division of Epidemiology, University of Minnesota School of Public Health, Minneapolis, Minnesota, USA
    J Vasc Surg 39:474-81. 2004
  6. ncbi Vascular disease, hypertension, and prevention: "from endothelium to clinical events"
    Alan T Hirsch
    Vascular Medicine Program, Cardiovascular Division, Minnesota Vascular Diseases Center, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    J Am Coll Cardiol 42:377-9. 2003
  7. ncbi National health care costs of peripheral arterial disease in the Medicare population
    Alan T Hirsch
    Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, MN 55454 1015, USA
    Vasc Med 13:209-15. 2008
  8. ncbi Undertreatment of dyslipidemia in peripheral arterial disease and other high-risk populations: an opportunity for cardiovascular disease reduction
    Alan T Hirsch
    Vascular Medicine Programs, Cardiovascular Division, Minnesota Vascular Diseases Center, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Vasc Med 7:323-31. 2002
  9. ncbi Images in clinical medicine. Infrarenal aortic occlusion
    Alan T Hirsch
    Abbott Northwestern Hospital, Minneapolis, MN 55407, USA
    N Engl J Med 359:735. 2008
  10. ncbi Peripheral arterial disease detection, awareness, and treatment in primary care
    A T Hirsch
    Vascular Medicine Program, Minnesota Vascular Diseases Center, Mayo Mail Code 508, University of Minnesota Medical School, 420 Delaware St, SE, Minneapolis, MN 55455, USA
    JAMA 286:1317-24. 2001

Detail Information

Publications59

  1. ncbi Gaps in public knowledge of peripheral arterial disease: the first national PAD public awareness survey
    Alan T Hirsch
    Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Ste 300, 1300 S 2nd St, Minneapolis, MN 55454, USA
    Circulation 116:2086-94. 2007
    ..Nevertheless, public knowledge of PAD as a morbid and mortal disease has not been previously assessed...
  2. ncbi Special communication: mandate for creation of a national peripheral arterial disease public awareness program: an opportunity to improve cardiovascular health
    Alan T Hirsch
    Division of Epidemiology, University of Minnesota School of Public Health, and Vascular Medicine Program, Minneapolis Heart Institute, Rochester, MN, USA
    Angiology 55:233-42. 2004
    ....
  3. ncbi The potential role of angiotensin-converting enzyme inhibition in peripheral arterial disease
    Alan T Hirsch
    Vascular Medicine Program, Minneapolis Heart Institute, and Division of Epidemiology, University of Minnesota School of Public Health, Minneapolis, MN 55454, USA
    Vasc Med 8:273-8. 2003
    ..These studies suggest that ACE inhibitor therapy should be considered in the routine management of individuals with PAD, regardless of whether they have hypertension or left ventricular dysfunction...
  4. ncbi Mandate for creation of a national peripheral arterial disease public awareness program: an opportunity to improve cardiovascular health
    Alan T Hirsch
    Division of Epidemiology, University of Minnesota School of Public Health, and Vascular Medicine Program, Minneapolis Heart Institute, Rochester, MN, USA
    Vasc Endovascular Surg 38:121-30. 2004
    ....
  5. ncbi Mandate for creation of a national peripheral arterial disease public awareness program: an opportunity to improve cardiovascular health
    Alan T Hirsch
    Division of Epidemiology, University of Minnesota School of Public Health, Minneapolis, Minnesota, USA
    J Vasc Surg 39:474-81. 2004
    ..provides an overview of the National Heart, Lung, and Blood Institute PAD education meeting; and (5). outlines the "next steps" required to accomplish these goals...
  6. ncbi Vascular disease, hypertension, and prevention: "from endothelium to clinical events"
    Alan T Hirsch
    Vascular Medicine Program, Cardiovascular Division, Minnesota Vascular Diseases Center, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    J Am Coll Cardiol 42:377-9. 2003
  7. ncbi National health care costs of peripheral arterial disease in the Medicare population
    Alan T Hirsch
    Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, MN 55454 1015, USA
    Vasc Med 13:209-15. 2008
    ..The potential impact of earlier PAD detection and use of outpatient preventive strategies on total national PAD health care costs is unknown...
  8. ncbi Undertreatment of dyslipidemia in peripheral arterial disease and other high-risk populations: an opportunity for cardiovascular disease reduction
    Alan T Hirsch
    Vascular Medicine Programs, Cardiovascular Division, Minnesota Vascular Diseases Center, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Vasc Med 7:323-31. 2002
    ..The use of statin medications in high-risk groups such as PAD patients could prove particularly beneficial in reducing cardiovascular morbidity and mortality and therefore merits prospective clinical investigation...
  9. ncbi Images in clinical medicine. Infrarenal aortic occlusion
    Alan T Hirsch
    Abbott Northwestern Hospital, Minneapolis, MN 55407, USA
    N Engl J Med 359:735. 2008
  10. ncbi Peripheral arterial disease detection, awareness, and treatment in primary care
    A T Hirsch
    Vascular Medicine Program, Minnesota Vascular Diseases Center, Mayo Mail Code 508, University of Minnesota Medical School, 420 Delaware St, SE, Minneapolis, MN 55455, USA
    JAMA 286:1317-24. 2001
    ..Peripheral arterial disease (PAD) is a manifestation of systemic atherosclerosis that is common and is associated with an increased risk of death and ischemic events, yet may be underdiagnosed in primary care practice...
  11. ncbi The Minnesota Regional Peripheral Arterial Disease Screening Program: toward a definition of community standards of care
    A T Hirsch
    Vascular Medicine Program, Minnesota Vascular Diseases Center, University of Minnesota Medical School, Minneapolis 55455, USA
    Vasc Med 6:87-96. 2001
    ..These data can assist in the future development of PAD awareness, education, and treatment programs...
  12. ncbi Albuminuria and peripheral arterial disease: results from the multi-ethnic study of atherosclerosis (MESA)
    K Wattanakit
    Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN 55454 1015, United States
    Atherosclerosis 201:212-6. 2008
    ..The association of albuminuria with cardiovascular disease (CVD) is increasingly recognized, but its association with peripheral arterial disease (PAD) is not well characterized in subjects with or without diabetes...
  13. ncbi Risk factors for peripheral arterial disease incidence in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study
    Keattiyoat Wattanakit
    Division of Epidemiology, School of Public Health, University of Minnesota, Suite 300, 1300 South 2nd Street, Minneapolis, MN 55454-1015, USA
    Atherosclerosis 180:389-97. 2005
    ..CONCLUSION: These markers might be useful to identify individuals with diabetes at particular risk for PAD...
  14. ncbi Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication
    L T Cooper
    Mayo Clinic and Foundation, Cardiovascular Division, Rochester, MN 55905, USA
    Vasc Med 6:235-9. 2001
    ..Future clinical trials of bFGF protein should carefully monitor renal function and consider alternative dosing schedules and drug administration routes...
  15. ncbi A patient-derived perspective of health-related quality of life with peripheral arterial disease
    Diane Treat-Jacobson
    University of Minnesota, USA
    J Nurs Scholarsh 34:55-60. 2002
    ..To evaluate the effects of peripheral artery disease (PAD) on health-related quality of life (HRQoL) from the patient's perspective to establish a foundation for systematic PAD-specific HRQoL assessment in this population...
  16. ncbi Design of the multicenter standardized supervised exercise training intervention for the claudication: exercise vs endoluminal revascularization (CLEVER) study
    Ulf G Bronas
    School of Nursing, University of Minnesota, Minneapolis, MN 55455, USA
    Vasc Med 14:313-21. 2009
    ....
  17. ncbi Process of care and outcomes in patients with peripheral arterial disease
    Tracie C Collins
    Houston Center for Quality of Care and Utilization Studies, and Section of Health Services Research, Baylor College of Medicine, Houston, Texas, USA
    J Gen Intern Med 22:942-8. 2007
    ..We investigated the association of process of care measures with adverse limb and systemic events in patients with peripheral arterial disease (PAD)...
  18. ncbi Correlates and consequences of venous thromboembolism: The Iowa Women's Health Study
    Pamela L Lutsey
    University of Minnesota, Minneapolis, USA
    Am J Public Health 100:1506-13. 2010
    ..We sought to document incidence, case-fatality, and recurrence rates of venous thromboembolism (VTE) in women and to explore the relationship of demographic, lifestyle, and anthropometric factors to VTE incidence...
  19. ncbi Developing pharmaceutical treatments for peripheral artery disease
    Daniel A Duprez
    Cardiovascular Division, Mayo Mail Code 508, University of Minnesota, 420 Delaware St SE, Minneapolis, MN 55455, USA
    Expert Opin Investig Drugs 12:101-8. 2003
    ....
  20. ncbi International heterogeneity in diagnostic frequency and clinical outcomes of ascending aortic intramural hematoma
    Jamie M Pelzel
    Cardiovascular Division, University of Minnesota Medical School, Minneapolis, Minnesota, USA
    J Am Soc Echocardiogr 20:1260-8. 2007
    ..Differing diagnostic frequencies and management strategies for intramural hematoma (IMH) have been described in North American (NA)/European and Japanese/Korean studies...
  21. ncbi The efficacy and safety of enhanced external counterpulsation in patients with peripheral arterial disease
    Bhavik V Thakkar
    Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, MN 55407, USA
    Vasc Med 15:15-20. 2010
    ....
  22. ncbi Ankle-brachial index and hemostatic markers in the Atherosclerosis Risk in Communities (ARIC) study cohort
    Laura M Reich
    Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA
    Vasc Med 12:267-73. 2007
    ..56-4.65), for beta-TG was 1.80 (95% CI 1.12-2.88), and for CRP was 1.57 (95% CI 0.84-2.95). Plasma levels of hemostatic and inflammatory markers are elevated in PAD, suggesting these processes are involved in the pathophysiology of PAD...
  23. ncbi Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) Study
    Keattiyoat Wattanakit
    Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Suite 300, 1300 South Second Street, Minneapolis, MN 55454 1015, USA
    J Am Soc Nephrol 18:629-36. 2007
    ..56 (95% CI 1.13 to 2.14). Patients with CKD are at increased risk for incident PAD. Development of strategies for screening and prevention of PAD in this high-risk population seems warranted...
  24. ncbi Association of anger proneness, depression and low social support with peripheral arterial disease: the Atherosclerosis Risk in Communities Study
    Keattiyoat Wattanakit
    Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, MN 55454-1015, USA
    Vasc Med 10:199-206. 2005
    ..These findings may warrant confirmation in further studies and, if causal, could serve as a unique target for a PAD prevention trial...
  25. ncbi Effect of bilateral nephrectomy on active renin, angiotensinogen, and renin glycoforms in plasma and myocardium
    S A Katz
    Division of Nephrology, Hennepin County Medical Center, Minneapolis, Minn 55415 1829, USA
    Hypertension 30:259-66. 1997
    ..Control myocardial angiotensinogen concentrations are too low to result from simple diffusion equilibrium between plasma and the myocardial interstitium...
  26. ncbi PAD awareness, risk, and treatment: new resources for survival--the USA PARTNERS program
    A T Hirsch
    Vascular Medicine Program, Minnesota Vascular Diseases Center, University of Minnesota Medical School, Minneapolis 55455, USA
    Vasc Med 6:9-12. 2001
    ..Data obtained will form the basis of future clinical investigations to improve clinical care for PAD patients in the USA...
  27. ncbi Clinical significance of a high ankle-brachial index: insights from the Atherosclerosis Risk in Communities (ARIC) Study
    Keattiyoat Wattanakit
    Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN 55454, USA
    Atherosclerosis 190:459-64. 2007
    ..The clinical significance of a high ankle-brachial index (ABI), defined by the associated risk factor burden and ischemic risk, is largely unknown...
  28. ncbi Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)
    Christopher P Cannon
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 105:445-52. 2010
    ..In conclusion, approximately 1/4 of US patients with vascular disease are not treated with aspirin for secondary prevention, and 15% are not treated with any antithrombotic agent...
  29. ncbi A high ankle-brachial index is associated with increased cardiovascular disease morbidity and lower quality of life
    Matthew A Allison
    Department of Family and Preventive Medicine, University of California San Diego, California, USA
    J Am Coll Cardiol 51:1292-8. 2008
    ..The purpose of this study is to determine if an ankle-brachial index (ABI) >or=1.40 is associated with reduced quality of life (QoL)...
  30. ncbi The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) Program
    Judith G Regensteiner
    Department of Medicine, University of Colorado School of Medicine, Denver, CO 80262, USA
    Vasc Med 13:15-24. 2008
    ....
  31. ncbi Risk factor profile and management of cerebrovascular patients in the REACH Registry
    Joachim Rother
    Department of Neurology, Klinikum Minden, Hannover Medical School, Minden, Germany
    Cerebrovasc Dis 25:366-74. 2008
    ..We assessed these factors in 18,992 CVD patients within a worldwide registry of stable outpatients...
  32. ncbi International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    JAMA 295:180-9. 2006
    ..To date, no single international database has characterized the atherosclerosis risk factor profile or treatment intensity of individuals with atherothrombosis...
  33. ncbi Cost-effectiveness of exercise training to improve claudication symptoms in patients with peripheral arterial disease
    Charoen Treesak
    Faculty of Pharmacy, Srinakharinwirot University, Thailand
    Vasc Med 9:279-85. 2004
    ..The cost-effectiveness and availability of claudication treatments has national implications for future PAD care; however, data to inform these care choices can best be obtained in prospective clinical trials...
  34. ncbi Critical issues in peripheral arterial disease detection and management: a call to action
    Jill J F Belch
    Department of Medicine, Ninewells Hospitals and Medical School, Scotland
    Arch Intern Med 163:884-92. 2003
  35. ncbi Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial
    Emile R Mohler
    University of Pennsylvania School of Medicine, Philadelphia Heart Institute, Room 432, 51 North 39th Street, Philadelphia, PA 19104, USA
    J Am Coll Cardiol 41:1679-86. 2003
    ..In the current study, we hypothesized that beraprost would: 1) improve treadmill exercise performance and quality of life; and 2) decrease rates of ischemic events in patients with intermittent claudication...
  36. ncbi Exercise training for claudication
    Kerry J Stewart
    Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, USA
    N Engl J Med 347:1941-51. 2002
  37. ncbi Concomitant peripheral arterial disease and coronary artery disease: therapeutic opportunities
    John A Bittl
    Ocala Heart Institute, Munroe Regional Medical Center, Ocala, Fla 34474, USA
    Circulation 109:3136-44. 2004
  38. ncbi Peripheral arterial disease rehabilitation: a review
    Rita A Falcone
    Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Cardiopulm Rehabil 23:170-5. 2003
  39. ncbi The Claudication: Exercise Vs. Endoluminal Revascularization (CLEVER) study: rationale and methods
    Timothy P Murphy
    Rhode Island Hospital Vascular Disease Research Center and Brown Medical School Department of Diagnostic Imaging, Providence, RI 02903, USA
    J Vasc Surg 47:1356-63. 2008
    ....
  40. ncbi Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 90:625-8. 2002
  41. ncbi Peripheral arterial disease: medical care and prevention of complications
    David L Dawson
    Uniformed Services University of the Health Sciences, Bethesda, MD, USA
    Prev Cardiol 5:119-30. 2002
    ..When diagnosed early, both exercise and pharmacotherapy can ameliorate symptoms of claudication, augment functional performance, and improve quality of life...
  42. ncbi The continuum of risk: vascular pathophysiology, function, and structure
    Alan T Hirsch
    Circulation 110:2774-7. 2004
  43. ncbi Development of a multicenter peripheral arterial interventional database: the PVD-QI2
    Debabrata Mukherjee
    Gill Heart Institute, Division of Cardiovascular Medicine, Lexington, KY 40436-0200, USA
    Am Heart J 149:1003-8. 2005
    ....
  44. ncbi ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vas
    Alan T Hirsch
    J Am Coll Cardiol 47:1239-312. 2006
  45. ncbi "POBA Plus": will the balloon regain its luster?
    Timothy D Henry
    Circulation 118:1309-11. 2008
  46. ncbi Atherosclerotic risk factor reduction in peripheral arterial diseasea: results of a national physician survey
    Mary Mcgrae McDermott
    Departments of Medicine and Preventive Medicine, The Feinberg School of Medicine, Northwestern University, Evanston Ill 60611, USA
    J Gen Intern Med 17:895-904. 2002
    ..We documented physician-reported practice behavior, knowledge, and attitudes regarding atherosclerotic risk factor reduction in patients with PAD...
  47. ncbi Usefulness of increased skin cholesterol to identify individuals at increased cardiovascular risk (from the Predictor of Advanced Subclinical Atherosclerosis study)
    James H Stein
    University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Am J Cardiol 101:986-91. 2008
    ..SC may be a useful test for cardiovascular risk prediction...
  48. ncbi Regional Angiogenesis with Vascular Endothelial Growth Factor (VEGF) in peripheral arterial disease: Design of the RAVE trial
    Sanjay Rajagopalan
    Department of Internal Medicine, Section of Vascular Medicine, Division of Cardiology, University of Michigan Health System, Ann Arbor 48109 0273, USA
    Am Heart J 145:1114-8. 2003
    ..10)) to patients with severe IC caused by infrainguinal disease...
  49. ncbi Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events
    Peter A Ringleb
    Department of Neurology, University of Heidelberg Medical School, Heidelberg, Germany
    Stroke 35:528-32. 2004
    ..039). CONCLUSIONS: CAPRIE patients with a history of prior symptomatic atherosclerotic disease had a high rate of subsequent ischemic events. The absolute benefit of clopidogrel over ASA seemed to be amplified in such high-risk patients...
  50. ncbi ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Sur
    Alan T Hirsch
    Circulation 113:e463-654. 2006
  51. ncbi The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design
    E Magnus Ohman
    Division of Cardiology, Duke University Medical Center, Durham, NC, USA
    Am Heart J 151:786.e1-10. 2006
    ....
  52. ncbi Treatment of peripheral arterial disease--extending "intervention" to "therapeutic choice"
    Alan T Hirsch
    N Engl J Med 354:1944-7. 2006
  53. ncbi ACC/AHA Guidelines for the Management of Patients with Peripheral Arterial Disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society
    Alan T Hirsch
    J Vasc Interv Radiol 17:1383-97; quiz 1398. 2006
  54. ncbi Impact of carotid endarterectomy on medical secondary prevention after a stroke or a transient ischemic attack: results from the Reduction of Atherothrombosis for Continued Health (REACH) registry
    Emmanuel Touze
    Faculté de Médecine René Descartes, Universite Paris 5, EA 4055, Department of Neurology, Paris, France
    Stroke 37:2880-5. 2006
    ..Whether a history of carotid endarterectomy influences patient compliance with medical treatments and physician attitude toward treatments after ischemic stroke or transient ischemic attack (TIA) is not well known...
  55. ncbi One-year cardiovascular event rates in outpatients with atherothrombosis
    Ph Gabriel Steg
    Departement de Cardiologie, Hopital Bichat Claude Bernard, Paris, France
    JAMA 297:1197-206. 2007
    ....
  56. ncbi Utility and barriers to performance of the ankle-brachial index in primary care practice
    Emile R Mohler
    University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Vasc Med 9:253-60. 2004
    ..The ABI is a simple peripheral arterial disease detection tool that can be successfully applied in primary care office practices...
  57. ncbi Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy
    William R Hiatt
    Department of Medicine, University of Colorado School of Medicine, Section of Vascular Medicine, and the Colorado Prevention Center, Denver, CO 80203, USA
    Vasc Med 9:18-25. 2004
    ..These data indicate that selective serotonin receptor blockade does not improve exercise tolerance or quality of life in individuals with claudication...
  58. ncbi Atherosclerotic Vascular Disease Conference: Writing Group V: medical decision making and therapy
    Mark A Creager
    Circulation 109:2634-42. 2004
  59. ncbi Carotid intima-media thickness testing by non-sonographer clinicians: the office practice assessment of carotid atherosclerosis study
    Claudia E Korcarz
    University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53792, USA
    J Am Soc Echocardiogr 21:117-22. 2008
    ....